var data={"title":"Bupivacaine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bupivacaine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5766?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bupivacaine-drug-information\" class=\"drug drug_general\">see &quot;Bupivacaine: Drug information&quot;</a> and <a href=\"topic.htm?path=bupivacaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bupivacaine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708636\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Obstetrical anesthesia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The bupivacaine 0.75% concentration is not recommended for obstetrical anesthesia. There have been reports of cardiac arrest with difficult resuscitation or death during use of bupivacaine for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% concentration should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142923\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bupivacaine Spinal;</li>\n      <li>Marcaine;</li>\n      <li>Marcaine Preservative Free;</li>\n      <li>Marcaine Spinal;</li>\n      <li>P-Care M;</li>\n      <li>ReadySharp Bupivacaine;</li>\n      <li>Sensorcaine;</li>\n      <li>Sensorcaine-MPF;</li>\n      <li>Sensorcaine-MPF Spinal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142924\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Marcaine;</li>\n      <li>Sensorcaine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057024\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Local Anesthetic, Injectable</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442152\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient; should only be administered under the supervision of a qualified physician experienced in the use of anesthetics. Preservative-free formulations are recommended for administration into the CNS space (eg, epidural, caudal, spinal). Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Mulroy 2010). Dosing units variable (mL/kg, <b>mg/kg</b>); use extra precaution to ensure accuracy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Central nerve block/anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Caudal block:</i> Limited data available: Term neonate: Usual concentration &le;0.25% solution: Usual reported dose range: 0.5 to 1.25 mL/kg; dose should not exceed 2.5 <b>mg/kg</b>. Routine use of concentrations <span style=\"text-decoration: underline\">&lt;</span>0.25% have been suggested to reduce risk of bupivacaine cardiotoxicity (Cot&eacute; 2013; Deng 2008; Lin 2010; L&ouml;nnqvist 2010; Kost-Byerly 2008; Schwartz 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Epidural Block:</i> Limited data available: Term neonate: Usual concentration &le;0.25% solution: Usual dose: 1 mL/kg; dose should not exceed 2.5 <b>mg/kg</b>; required dose may vary; among other factors, dose also dependent on desired dermatome level and corresponding volume of epidural space (Cot&eacute; 2013; Miller 2015). If repeat injections necessary, a decreased dose is necessary to prevent drug accumulation. Some experts suggest if at least 45 minutes since initial dose, reduce dose to <sup>1</sup>/<sub>3</sub> of the initial or if at least 90 minutes since initial dose, then reduce dose to half of the initial. If additional doses are necessary, doses should be reduced to half of the previous dose (Miller 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Epidural, continuous infusion</i>: Limited data available (Berde 1992; Lonnqvist 2010; Miller 2015): <b>Note:</b> Use has generally been replaced by other agents (eg, ropivacaine) (L&ouml;nnqvist 2010; Moriarty 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: Usual concentration &le;0.25% solution: 2 to 2.5 <b>mg/kg</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infusion: Usual infusion concentration range 0.05 to 0.25% solution: 0.2 to 0.25 <b>mg/</b>kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral nerve blocks</b>: Limited data available (J&ouml;hr 2015): <b>Note:</b> Dose volume and concentration varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Term neonate: Usual Concentration: 0.125 to 0.25% solution: Volume of dose (mL/kg, specific to site and may be variable among patients) and not to exceed the maximum dose: 2 <b>mg/kg </b>(Cot&eacute; 2013; Miller 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Commonly suggested doses (Cot&eacute; 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Head and neck:</i> 0.05 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Upper extremity</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Brachial plexus: 0.2 to 0.3 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Digital nerve: 0.05 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Truncal blocks:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Transversus abdominis plane: 0.2 to 0.5 mL/kg (J&ouml;hr 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Rectus sheath: 0.1 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Ilioinguinal: 0.075 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Lower extremity blocks</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Femoral nerve: 0.2 to 0.3 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sciatic nerve: 0.2 to 0.3 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spinal Anesthesia: </b>Limited data available (Walker 2012): Usual concentration: 0.25 or 0.5% solution (isobaric) or 0.75% bupivacaine in 8.25% dextrose solution (hyperbaric): Intrathecal: 0.5 to 1 <b>mg/kg</b> (Bonnett 2004; Cot&eacute; 2013; Frawley 2009; J&ouml;hr 2015; Rochette 2005; Somri 2007; Williams 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057018\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=bupivacaine-drug-information\" class=\"drug drug_general\">see &quot;Bupivacaine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Preservative-free formulations are recommended for administration into the CNS space (eg, epidural, caudal, spinal) Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Mulroy 2010). Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Mulroy 2010). Should only be administered under the supervision of a qualified physician experienced in the use of anesthetics</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: In pediatric patients, dosing should be based on lean body mass (Cot&eacute; 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Central nerve block/anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Caudal block:</i> Reported dosing variable based on procedure; dependent on necessary dermatome level and corresponding volume of space:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: Limited data available: Usual concentration &le;0.25% solution with or without epinephrine: Usual reported dose range: 0.5 to 1.3 mL/kg (maximal volume of drug: 20 mL); dose should not exceed 2 <b>mg/kg</b> plain solution, or 3 <b>mg/kg</b> with epinephrine. In infants, routine use of concentrations <span style=\"text-decoration: underline\">&lt;</span>0.25% have been suggested to reduce risk of bupivacaine cardiotoxicity (Cot&eacute; 2013; Ingelmo 2007; Ivani 1998; Ivani 2002; Karkera 2016; Miller 2015; Payne 1993; Schrock 2003; Schwartz 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Usual concentration 0.25 to 0.5% solution with or without epinephrine: 15 to 30 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Epidural block</i>: Reported dosing variable; among other factors, dose dependent on necessary dermatome level and corresponding volume of epidural space (Cot&eacute; 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: Limited data available: Usual concentration &le;0.25% with or without epinephrine: 0.7 to 0.75 mL/kg; maximum dose: 2.5 <b>mg/kg</b>; <b>Note: </b>For infants (particularly young infants), if repeat injections necessary, a decreased dose may be necessary to prevent drug accumulation. Some experts suggest if at least 45 minutes since initial dose, reduce dose to <sup>1</sup>/<sub>3</sub> of the initial or if at least 90 minutes since initial dose, then reduce dose to half of the initial. If additional doses are necessary, doses should be reduced to half of the previous dose (Ivani 1999; Miller 2015; Monsel 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: Limited data available: Usual concentration 0.25% solution: Initial: 0.3 to 0.6 mL/kg (maximal volume of drug: 20 mL); maximum dose: 2.5 <b>mg/kg</b> (Ingelmo 2007; Ingelmo 2007a)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 0.25% or 0.5% solution: 10 to 20 mL administered in 3 to 5 mL increments; if high degree of muscle relaxation and prolonged effects needed, may consider 0.75% solution: 10 to 20 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Epidural, continuous infusion: </i>Limited data available in infants and children &lt;12 years (Berde 1992; Miller 2015; Moriarty 2012): <b>Note:</b> Use has generally been replaced by other agents (eg, ropivacaine) (Miller 2015; Moriarty 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: Usual concentration: 0.25%: 2 to 2.5 <b>mg/kg</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants &lt;4 months: 0.2 <b>mg</b>/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants &ge;4 months: 0.25 <b>mg</b>/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents: 0.3 <b>mg</b>/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peripheral nerve block: </b>Limited data available in infants and children: <b>Note:</b> Dose varies with location of block (ie, procedure), depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months and Children: Usual concentration 0.125% or 0.25% solution with or without epinephrine: The volume of dose (mL/kg) and concentration of solution are site specific based upon anatomy and variable among patients and procedure; see below ranges. For infants &lt;6 months, maximum doses should be reduced by 30% (Cot&eacute; 2013; Miller 2015). Maximum dose plain solution: 2 <b>mg/kg</b> or 150 mg whichever is less or maximum dose with epinephrine: 3 <b>mg/kg</b> or 200 mg of bupivacaine whichever is less.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Commonly suggested doses (Cot&eacute; 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Head and neck:</i> 0.05 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Upper extremity</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Brachial plexus: 0.2 to 0.3 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Digital nerve: 0.05 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Truncal blocks:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Transversus abdominis plane: 0.2 to 0.5 mL (J&ouml;hr 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Rectus sheath: 0.1 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Ilioinguinal: 0.075 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Lower extremity blocks</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Femoral nerve: 0.2 to 0.3 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Sciatic nerve: 0.2 to 0.3 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: 0.25% or 0.5% solution with or without epinephrine: 5 mL; maximum daily dose: 400<b> mg/day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Local anesthesia</b>: Infants, Children, and Adolescents: Limited data in infants and children: Usual concentration 0.25% solution: Infiltrate area local; maximum dose in infants and children: 2.5 <b>mg/kg</b> or 150 mg whichever is less; maximum dose in adolescents: 175 mg (Cot&eacute; 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Local anesthesia:</b> Infiltration: 0.25% infiltrated locally; maximum: 175 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Caudal block (preservative free):</b> 15 to 30 mL of 0.25% or 0.5%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Epidural block (other than caudal block; preservative free):</b> Administer in 3 to 5 mL increments, allowing sufficient time to detect toxic manifestations of inadvertent IV or intrathecal administration: 10 to 20 mL of 0.25% or 0.5%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Surgical procedures requiring a high degree of muscle relaxation and prolonged effects only: 10 to 20 mL of 0.75% (<b>Note:</b> Not to be used in obstetrical cases.)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peripheral nerve block:</b> 5 mL of 0.25% or 0.5%; maximum: 400 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sympathetic nerve block:</b> 20 to 50 mL of 0.25%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Retrobulbar anesthesia: </b>2 to 4 mL of 0.75%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Spinal anesthesia:</b> Preservative-free solution of 0.75% bupivacaine in 8.25% dextrose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lower extremity and perineal procedures:</b> 1 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lower abdominal procedures:</b> 1.6 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Normal vaginal delivery:</b> 0.8 mL (higher doses may be required in some patients)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cesarean delivery:</b> 1 to 1.4 mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142906\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">P-Care M: 0.5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ReadySharp Bupivacaine: 0.5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Epidural, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% in NaCl 0.9% (250 mL); 0.25% in NaCl 0.9% (50 mL, 200 mL, 250 mL, 400 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marcaine: 0.25% (50 mL); 0.5% (50 mL) [contains methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sensorcaine: 0.25% (50 mL); 0.5% (50 mL) [contains methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25% (30 mL [DSC], 50 mL); 0.5% (50 mL); 0.1% in NaCl 0.9% (500 mL); 0.125% in NaCl 0.9% (550 mL, 600 mL, 750 mL); 0.2% in NaCl 0.9% (500 mL); 0.25% in NaCl 0.9% (500 mL, 550 mL, 600 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marcaine: 0.75% (10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marcaine Preservative Free: 0.25% (10 mL, 30 mL); 0.5% (10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sensorcaine-MPF: 0.25% (10 mL, 30 mL); 0.5% (10 mL, 30 mL); 0.75% (10 mL, 30 mL) [methylparaben free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25% (10 mL, 20 mL [DSC], 30 mL); 0.5% (10 mL, 20 mL [DSC], 30 mL); 0.75% (10 mL, 20 mL [DSC], 30 mL); 0.1% in NaCl 0.9% (400 mL [DSC]); 0.25% in NaCl 0.9% (550 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intrathecal, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.75% [7.5 mg/mL] (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intrathecal, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bupivacaine Spinal: 0.75% [7.5 mg/mL] (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marcaine Spinal: 0.75% [7.5 mg/mL] (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sensorcaine-MPF Spinal: 0.75% [7.5 mg/mL] (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Epidural, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25% in NaCl 0.9% (10 mL); 0.5% in NaCl 0.9% (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142891\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057028\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Solutions containing preservatives should not be used for epidural or caudal blocks; for epidural infusion, may use undiluted or diluted with preservative-free NS. Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Mulroy 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142919\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&#730;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057027\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Local or regional anesthesia; spinal anesthesia; anesthesia for diagnostic and therapeutic procedures and obstetrical procedures (FDA approved in ages &ge;12 years and adults); specific uses vary by product:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">0.25%: Local infiltration, peripheral nerve block, sympathetic block, caudal or epidural block</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">0.5%: Peripheral nerve block, caudal and epidural block</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">0.75% Retrobulbar block, epidural block. <b>Note:</b> Not for obstetrical anesthesia; reserve for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142970\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bupivacaine may be confused with mepivacaine, ropivacaine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marcaine&reg; may be confused with Narcan&reg;</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142967\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Most effects are dose related, and are often due to accelerated absorption from the injection site, unintentional intravascular injection, or slow metabolic degradation. The development of any central nervous system symptoms may be an early indication of more significant toxicity (seizure). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Cardiovascular: Bradycardia, cardiac arrest, heart block, hypotension, palpitations, ventricular arrhythmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, dizziness, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylactoid reaction, hypersensitivity reaction (urticaria, pruritus, angioedema) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Chondrolysis (continuous intra-articular administration), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Blurred vision, miosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Tinnitus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Apnea, hypoventilation (usually associated with unintentional subarachnoid injection during high spinal anesthesia) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Seizure; usually associated with unintentional subarachnoid injection during high spinal anesthesia: cranial nerve palsy, fecal incontinence, headache, loss of anal sphincter control, loss of perineal sensation, paralysis, paresthesia, persistent anesthesia, septic meningitis, sexual disorder (loss of function), urinary incontinence</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142911\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to bupivacaine hydrochloride, amide-type local anesthetics, or any component of the formulation; obstetrical paracervical block anesthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Use as intravenous regional anesthesia (Bier block) is considered contraindicated per accepted clinical practice due to reports of cardiac arrest and death.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Obstetric paracervical block anesthesia; severe shock and in heart block where there is inflammation and/or sepsis near the proposed injection site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142895\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: Bupivacaine-containing products have been associated with rare occurrences of arrhythmias, cardiac arrest, and death.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily shoulder joint) has occurred following infusion, with some patients requiring arthroplasty or shoulder replacement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest, especially when administered near the head or neck.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection or administration near the head or neck.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease including patients with hypotension or heart block. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acutely ill patients: Use with caution in acutely ill patients; dose reduction may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Debilitated patients: Use with caution in debilitated patients; dose reduction may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly; dose reduction may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Obstetrical anesthesia: <b> [US Boxed Warning]: The 0.75% concentration is not recommended for obstetrical anesthesia; cardiac arrest with difficult resuscitation or death has occurred. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Preservative-containing solutions: <b>Do not use solutions containing preservatives for caudal or epidural block.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sodium metabisulfite: May contain sodium metabisulfite; use caution in patients with asthma or a sulfite allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided. Intravenous regional anesthesia (Bier block) is not recommended; cardiac arrest and death have occurred with this method of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Test dose: A test dose is recommended prior to epidural administration (prior to initial dose) and all reinforcing doses with continuous catheter technique. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820018\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Infants may be at greater risk for bupivacaine toxicity because &alpha;<sub>1</sub>-acid-glycoprotein concentration, the major serum protein to which bupivacaine is bound, is lower in neonates and infants compared with older children leading to an increase of free fraction of local anesthetic; use epidural infusions with caution in neonates and infants and monitor closely. Fat emulsion has been used to manage local anesthetic toxicity (refer to Fat Emulsion monograph for additional information) (McCloskey 1992).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142957\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142900\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13100&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May increase the serum concentration of Bupivacaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine (Liposomal): Bupivacaine may enhance the adverse/toxic effect of Bupivacaine (Liposomal).  Management: Bupivacaine may be administered immediately before, or administered in the same admixture syringe as liposomal bupivacaine as long as the ratio of the milligram dose of bupivacaine to liposomal bupivacaine does not exceed 1:2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142902\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2233562\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Bupivacaine crosses the placenta. Bupivacaine is approved for use at term in obstetrical anesthesia or analgesia. <b>[U.S. Boxed Warning]: The 0.75% is not recommended for obstetrical anesthesia.</b> Bupivacaine 0.75% solutions have been associated with cardiac arrest following epidural anesthesia in obstetrical patients and use of this concentration is not recommended for this purpose. Use in obstetrical paracervical block anesthesia is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057026\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Toxicity: 2 to 4 mcg/mL; unbound bupivacaine: &ge;0.3 mcg/mL (Cot&eacute; 2013; Miller 2015); some data suggests that the rate of rise of the serum level is more predictive of toxicity than the actual value (Scott 1975)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142894\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142910\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Anesthesia (route and dose dependent): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> Epidural: Up to 17 minutes to spread to T6 dermatome (Scott 1980)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> Infiltration: Fast (Barash 2009); Dental injection: 2 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> Spinal: Within 1 minute; maximum dermatome level achieved within 15 minutes in most cases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration (route and dose dependent): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epidural: 2 to 7.7 hours (Barash 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infiltration: 2 to 8 hours (Barash 2009); Dental injection: Up to 7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Spinal: 1.5 to 2.5 hours (Hadzic 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>:  Infants: 3.9 &plusmn; 2 L/kg; Children: 2.7 &plusmn; 0.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 84% to 95% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; forms metabolite (pipecoloxylidine [PPX]) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination (age dependent): Neonates: 8.1 hours; Adults: 2.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Caudal, epidural, or peripheral nerve block: 30 to 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~6% unchanged)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Infants: 7.1 &plusmn; 3.2 mL/kg/minute; Children: 10 &plusmn; 0.7 mL/kg/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057033\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">For epidural infusion, lower dosages of bupivacaine may be effective when used in combination with opioid analgesics</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323027\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (ReadySharp Bupivacaine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (1): $247.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bupivacaine HCl (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (30 mL): $1.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (30 mL): $2.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (10 mL): $2.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bupivacaine HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (50 mL): $3.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (50 mL): $2.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bupivacaine HCl-NaCl (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1-0.9% (500 mL): $47.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125-0.9% (750 mL): $76.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2-0.9% (500 mL): $58.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25-0.9% (500 mL): $76.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.375-0.9% (100 mL): $32.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bupivacaine HCl-NaCl Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1-0.9% (250 mL): $18.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25-0.9% (250 mL): $28.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bupivacaine in Dextrose Intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75-8.25% (2 mL): $4.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Marcaine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (50 mL): $7.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (50 mL): $6.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (10 mL): $4.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Marcaine Preservative Free Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (10 mL): $3.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (10 mL): $4.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Marcaine Spinal Intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75-8.25% (2 mL): $5.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sensorcaine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (50 mL): $12.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (50 mL): $13.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sensorcaine-MPF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (30 mL): $8.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (30 mL): $8.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (10 mL): $5.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sensorcaine-MPF Spinal Intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75-8.25% (2 mL): $4.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Bupivacaine HCl-NaCl Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5-0.9% (10 mL): $5.89</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038543\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anawin (BD);</li>\n      <li>Anekain (HR);</li>\n      <li>Bucain (DE, HU, ID);</li>\n      <li>Bucaine (AE, BH, CY, EG, HU, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Bunascan Spinal (ID);</li>\n      <li>Bupicaina (AR);</li>\n      <li>Bupican (LK, QA);</li>\n      <li>Bupican Heavy (LK);</li>\n      <li>Bupine (PK);</li>\n      <li>Bupinest S.P. (PE);</li>\n      <li>Bupinex (PY, UY);</li>\n      <li>Bupiright (PH);</li>\n      <li>Bupivacain Jenapharm (DE);</li>\n      <li>Bupivacain-RPR (DE);</li>\n      <li>Bupivacain-RPR CO!2 (DE);</li>\n      <li>Bupivacaine Aguettant (FR);</li>\n      <li>Bupivacaine B. Braun (FR);</li>\n      <li>Buvacaina (EC);</li>\n      <li>Buvacainas (CO);</li>\n      <li>Buvanest Spinal (ID);</li>\n      <li>Carbostesin (AT, CH, DE);</li>\n      <li>Chirocaina (VE);</li>\n      <li>Chlorhydrate de Bupivacaine Dakota (FR);</li>\n      <li>Dolanaest (DE);</li>\n      <li>Duracain (BD);</li>\n      <li>Duracaine (CL);</li>\n      <li>Indevus Spinal Heavy (ID);</li>\n      <li>Inibsacain (ES);</li>\n      <li>Kamacaine (IL);</li>\n      <li>Macaine (ZA);</li>\n      <li>Marcain (AU, DK, FI, GB, HN, HU, ID, IE, IS, IT, JP, LK, MY, NO, NZ, PT, RU, SE, SG, VN);</li>\n      <li>Marcain Spinal (BG, DK, EG, IS, LT, PL, SI, SK);</li>\n      <li>Marcaina (BR, GT, SV);</li>\n      <li>Marcaine (AE, BE, BG, BH, CY, CZ, EE, EG, FR, GR, HK, IL, IQ, IR, JO, KR, KW, LB, LT, LU, LV, LY, NL, OM, PH, PL, QA, SA, SI, SK, SY, TH, TR, TW, YE);</li>\n      <li>Marcaine Heavy (KR);</li>\n      <li>Marcaine Plain (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Marcaine Spinal Heavy (VN);</li>\n      <li>Markayin (UA);</li>\n      <li>Markayin Spinal (UA);</li>\n      <li>Nerkein (BD);</li>\n      <li>Picain (FI);</li>\n      <li>Pinacain (BD);</li>\n      <li>Pucaine (KR);</li>\n      <li>Recain (ID);</li>\n      <li>Regivell (PH);</li>\n      <li>Sanspen (PH);</li>\n      <li>Senpivac (PH);</li>\n      <li>Sensorcaine (IN, PH);</li>\n      <li>Sivicaine Heavy (BD);</li>\n      <li>Spica Spinal (ID);</li>\n      <li>Ultracaine (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Berde CB, &ldquo;Convulsions Associated With Pediatric Regional Anesthesia,&rdquo; <i>Anesth Analg</i>, 1992, 75(2):164-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/1632529 /pubmed\" target=\"_blank\" id=\"1632529 \">1632529 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonnet MP, Larousse E, Asehnoune K, Benhamou D. Spinal anesthesia with bupivacaine decreases cerebral blood flow in former preterm infants. <i>Anesth Analg</i>. 2004;98(5):1280-1283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/15105200/pubmed\" target=\"_blank\" id=\"15105200\">15105200</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bupivacaine injection, solution [prescribing information]. Lake Forest, IL: Hospira, Inc.; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bupivacaine Spinal injection, solution [prescribing information]. Lake Forest, IL: Hospira, Inc.; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cot&eacute; CJ, ed. <i>A Practice of Anesthesia for Infants and Children</i>. 5th ed.Philadelphia, PA: Elsevier Inc; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deng M, Wang X, Wang L, Zheng S. The hemodynamic effects of newborn caudal anesthesia assessed by transthoracic echocardiography: a randomized, double-blind, controlled study. <i>Paediatr Anaesth</i>. 2008;18(11):1075-1081.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/18950332/pubmed\" target=\"_blank\" id=\"18950332\">18950332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Desparmet J, Meistelman C, Barre J, et al, &ldquo;Continuous Epidural Infusion of Bupivacaine for Postoperative Pain Relief in Children,&rdquo; <i>Anesthesiology</i>, 1987, 67(1):108-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/ 3605712 /pubmed\" target=\"_blank\" id=\" 3605712 \"> 3605712 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frawley G, Smith KR, Ingelmo P. Relative potencies of bupivacaine, levobupivacaine, and ropivacaine for neonatal spinal anaesthesia. <i>Br J Anaesth</i>. 2009;103(5):731-738.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/19767606/pubmed\" target=\"_blank\" id=\"19767606\">19767606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ingelmo PM, Bendall EJ, Frawley G, et al. Bupivacaine caudal epidural anesthesia: assessing the effect of general anesthetic technique on block onset. <i>Paediatr Anaesth</i>. 2007;17(3):255-262.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/17263741/pubmed\" target=\"_blank\" id=\"17263741\">17263741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ingelmo P, Locatelli BG, Frawley G, et al. The optimum initial pediatric epidural bolus: a comparison of four local anesthetic solutions. <i>Paediatr Anaesth</i>. 2007a;17(12):1166-1175.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/17986035/pubmed\" target=\"_blank\" id=\"17986035\">17986035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ivani G, Lampugnani E, Torre M, et al. Comparison of ropivacaine with bupivacaine for paediatric caudal block. <i>Br J Anaesth</i>. 1998;81(2):247-248.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/9813532/pubmed\" target=\"_blank\" id=\"9813532\">9813532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ivani G, Lampugnani E, De Negri P, Lonnqvist PA, Broadman L. Ropivacaine vs bupivacaine in major surgery in infants. <i>Can J Anaesth</i>. 1999;46(5 Pt 1):467-469.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/10349927/pubmed\" target=\"_blank\" id=\"10349927\">10349927</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ivani G, DeNegri P, Conio A, et al. Comparison of racemic bupivacaine, ropivacaine, and levo-bupivacaine for pediatric caudal anesthesia: effects on postoperative analgesia and motor block. <i>Reg Anesth Pain Med</i>. 2002;27(2):157-161.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/ 3605712 /pubmed\" target=\"_blank\" id=\" 3605712 \"> 3605712 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    J&ouml;hr M. Regional anaesthesia in neonates, infants and children: an educational review. <i>Eur J Anaesthesiol</i>. 2015;32(5):289-297.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/25693139/pubmed\" target=\"_blank\" id=\"25693139\">25693139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karkera MM, Harrison DR, Aunspaugh JP, Martin TW. Assessing caudal block concentrations of bupivacaine with and without the addition of intravenous fentanyl on postoperative outcomes in pediatric patients: a retrospective review. <i>Am J Ther</i>. 2016;23(3):e792-e798.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/24832387/pubmed\" target=\"_blank\" id=\"24832387\">24832387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kost-Byerly S, Jackson EV, Yaster M, Kozlowski LJ, Mathews RI, Gearhart JP. Perioperative anesthetic and analgesic management of newborn bladder exstrophy repair. <i>J Pediatr Urol</i>. 2008;4(4):280-285.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/18644530/pubmed\" target=\"_blank\" id=\"18644530\">18644530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin EP, Aronson LA. Successful resuscitation of bupivacaine-induced cardiotoxicity in a neonate. <i>Paediatr Anaesth</i>. 2010;20(10):955-957.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/20849501/pubmed\" target=\"_blank\" id=\"20849501\">20849501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    L&ouml;nnqvist PA. Regional anaesthesia and analgesia in the neonate. <i>Best Pract Res Clin Anaesthesiol</i>. 2010;24(3):309-321.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/21033009/pubmed\" target=\"_blank\" id=\"21033009\">21033009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luz G, Innerhofer P, Bachmann B, et al, &ldquo;Bupivacaine Plasma Concentrations During Continuous Epidural Anesthesia in Infants and Children,&rdquo; <i>Anesth Analg</i>, 1996, 82(2):231-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/8561318 /pubmed\" target=\"_blank\" id=\"8561318 \">8561318 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCloskey JJ, Haun SE, and Deshpande JK, &ldquo;Bupivacaine Toxicity Secondary to Continuous Caudal Epidural Infusion in Children,&rdquo; <i>Anesth Analg</i>, 1992, 75(2):287-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/1340763/pubmed\" target=\"_blank\" id=\"1340763\">1340763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, ed. <i>Miller's Anesthesia</i>. 8th ed. Philadelphia, PA: Elsevier, Inc; 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/1340763/pubmed\" target=\"_blank\" id=\"1340763\">1340763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monsel A, Salvat-Toussaint A, Durand P, et al. The transesophageal Doppler and hemodynamic effects of epidural anesthesia in infants anesthetized with sevoflurane and sufentanil.<i> Anesth Analg</i>. 2007;105(1):46-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/17578955/pubmed\" target=\"_blank\" id=\"17578955\">17578955</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulroy MF, Hejtmanek MR. Prevention of local anesthetic systemic toxicity. <i>Reg Anesth Pain Med</i>. 2010;35(2):177-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/20216035/pubmed\" target=\"_blank\" id=\"20216035\">20216035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Payne KA, Hendrix MR, Wade WJ. Caudal bupivacaine for postoperative analgesia in pediatric lower limb surgery. <i>J Pediatr Surg</i>. 1993;28(2):155-157.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/8437068/pubmed\" target=\"_blank\" id=\"8437068\">8437068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rochette A, Troncin R, Raux O, et al. Clonidine added to bupivacaine in neonatal spinal anesthesia: a prospective comparison in 124 preterm and term infants. <i>Paediatr Anaesth</i>. 2005;15(12):1072-1077.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/16324026/pubmed\" target=\"_blank\" id=\"16324026\">16324026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott DB, &ldquo;Evaluation of Clinical Tolerance of Local Anaesthetic Agents,&rdquo; <i>Br J Anaesth</i>, 1975, 47:328-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/1148109 /pubmed\" target=\"_blank\" id=\"1148109 \">1148109 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schrock CR, Jones MB. The dose of caudal epidural analgesia and duration of postoperative analgesia. <i>Paediatr Anaesth</i>. 2003;13(5):403-408.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/12791113/pubmed\" target=\"_blank\" id=\"12791113\">12791113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwartz DA, Raghunathan K, Connelly NR. Reply to 'Successful resuscitation of bupivacaine-induced cardiotoxicity in a neonate'. <i>Paediatr Anaesth</i>. 2010;20(12):1136-1137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/21199124/pubmed\" target=\"_blank\" id=\"21199124\">21199124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Somri M, Tome R, Yanovski B, et al. Combined spinal-epidural anesthesia in major abdominal surgery in high-risk neonates and infants. <i>Paediatr Anaesth</i>. 2007;17(11):1059-1065.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/17897271/pubmed\" target=\"_blank\" id=\"17897271\">17897271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    William JM, Stoddart PA, Williams SA, Wolf AR. Post-operative recovery after inguinal herniotomy in ex-premature infants: comparison between sevoflurane and spinal anaesthesia. <i>Br J Anaesth</i>. 2001;86(3):366-371.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupivacaine-pediatric-drug-information/abstract-text/11573526/pubmed\" target=\"_blank\" id=\"11573526\">11573526</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13100 Version 138.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708636\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F142923\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F142924\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057024\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442152\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057018\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F142906\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F142891\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057028\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F142919\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057027\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F142970\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F142967\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F142911\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F142895\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820018\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F142957\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F142900\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F142902\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2233562\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1057026\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F142894\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F142910\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1057033\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323027\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038543\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13100|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bupivacaine-drug-information\" class=\"drug drug_general\">Bupivacaine: Drug information</a></li><li><a href=\"topic.htm?path=bupivacaine-patient-drug-information\" class=\"drug drug_patient\">Bupivacaine: Patient drug information</a></li></ul></div></div>","javascript":null}